McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the period ended September 30, 2008 (the second quarter of fiscal year 2009). McKesson operates in two primary segments: Distribution Solutions (pharmaceutical, medical-surgical, and health/beauty distribution) and Technology Solutions (software, services, and hardware for healthcare providers). The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Quarter Ended Sep 30, 2008 | Six Months Ended Sep 30, 2008 |
|---|---|---|
| Revenues | $26,574 million | $53,278 million |
| Net Income | $327 million | $562 million |
| Diluted EPS | $1.17 | $2.00 |
| Gross Profit Margin | 4.90% | 4.82% |
| Operating Income | $381 million | $752 million |
| Cash from Operations (6mo) | $548 million | |
| Cash and Equivalents | $1,123 million (as of Sep 30, 2008) | |
| Long-Term Debt | $1,795 million | |
| Working Capital | $2,390 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% year-over-year for both the quarter and the six-month period, driven primarily by the Distribution Solutions segment (9% growth).
- Profitability Surge: Net income increased 32% for the quarter and 17% for the six months. This was significantly aided by a $76 million net income tax benefit from the lapsing of statutes of limitations on previously unrecognized tax benefits.
- EPS Expansion: Diluted EPS rose 41% for the quarter and 25% for the six months, benefiting from the tax benefit, improved segment performance, and share repurchases reducing the share count (280 million diluted shares vs. 299 million prior year).
- Segment Performance:
- Distribution Solutions: Operating profit increased 11% (quarter) and 12% (six months). Gross margin improved by 11-13 basis points due to higher generic drug sales and a favorable mix shift away from lower-margin warehouse sales.
- Technology Solutions: Operating profit increased 8% for the quarter but decreased 17% for the six months, impacted by a change in product mix and the recognition of deferred revenues in the prior year.
- Acquisitions: The company acquired McQueary Brothers Drug Company ($191 million) in May 2008 and Oncology Therapeutics Network (OTN) in October 2007, both contributing to revenue growth.
Guidance, Outlook, and Risks
- Dividend Increase: The Board increased the quarterly dividend from $0.06 to $0.12 per share, effective April 2008.
- Share Repurchases: The company has $980 million remaining under its current repurchase plans as of September 30, 2008. It repurchased 4 million shares in the quarter.
- Subsequent Event: In October 2008, McKesson agreed to sell its specialty pharmacy business (within Distribution Solutions). The sale is expected to close in Q3 2009 and is not expected to be material.
- Legal Proceedings: The company faces significant litigation regarding Average Wholesale Price (AWP) and RICO claims. Plaintiffs in the "New England Carpenters I" case claim damages of $3.7 billion (trebled under RICO) for the certified class period. The company believes it has valid defenses but notes outcomes are uncertain.
- Market Risks: Key risks include changes in the U.S. healthcare regulatory environment, competition, drug price inflation/deflation, and the potential for substantial defaults by large customers.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the one-time nature of the $76 million tax benefit and its impact on the effective tax rate (13.7% for the quarter vs. 31.2% prior year).
- Legal Exposure: Review the status of the "New England Carpenters" and related AWP litigation, specifically the potential for treble damages.
- Working Capital Trends: Monitor the decrease in cash and cash equivalents ($1,362M to $1,123M) and the utilization of the $1.0 billion accounts receivable sales facility.
- Acquisition Integration: Assess the integration progress and synergy realization from the McQueary Brothers and OTN acquisitions.
- Specialty Pharmacy Sale: Confirm the closing timeline and financial impact of the pending sale of the specialty pharmacy business.